Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Market Resilience | Thermo Fisher Scientific navigates revenue challenges while maintaining strong positioning in Life Science Tools & Diagnostics sector, with promising signs in non-COVID markets. |
Bioproduction Boost | Explore the momentum in bioproduction within the Life Sciences Solutions segment, positioning Thermo Fisher for sustained growth and market leadership. |
China Conundrum | Delve into Thermo Fisher's complex China market outlook, balancing economic uncertainties with potential benefits from stimulus efforts and growth in specific drug segments. |
Analyst Perspectives | Average price target of $660, reflecting mixed views on Thermo Fisher's medium-term potential despite consistent performance in exceeding guidance. |
Metrics to compare | TMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTMOPeersSector | |
---|---|---|---|---|
P/E Ratio | 33.3x | −6.9x | −0.7x | |
PEG Ratio | 7.25 | −0.15 | 0.00 | |
Price/Book | 4.2x | 2.3x | 2.6x | |
Price / LTM Sales | 4.8x | 3.2x | 3.2x | |
Upside (Analyst Target) | 23.6% | 27.1% | 46.4% | |
Fair Value Upside | Unlock | 9.3% | 6.9% | Unlock |